The next shoe is set to drop in the high-flying immuno-oncology space, with genetically modified cell therapies close to becoming a reality. As these therapies are forecast to quickly become one of the fastest-growing segments of the $100 billion oncology market in the next few years, investors may want to consider taking a position in this emerging field before the first therapy reaches the market.
Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.
The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>
William Patalon III
I learned a lot of things during the three decades I’ve spent watching, chronicling and digging deep into the machinations of the world’s public companies.
And one of the key lessons I learned was also one of the most powerful when it comes to making money.
The lesson: When troubled companies make serious upgrades in their executive ranks,....More>>>
"Short Sellers Retreat Amid Rally," ran the headline in the Wall Street Journal. Curious readers stopped and stared. It was the premise of the headline that arrested them. Who knew that there was even one bear left to give ground at the 100-month mark of the post-2008 levitation? El toro is the topic at hand. It's a most unusual bull market (we count as one the updrafts....More>>>
Stocks edged higher today despite Donald Trump trashing the health care sector in his press conference today.
The S&P 500 rose 0.3% to 2,275.32 today, while the Dow Jones Industrial Average gained 98.75 points, or 0.5%, to 19,954.28. The Nasdaq Composite advanced 0.2% to5,563.65–and hit its fifth consecutive high–despite the fact that biotech stocks tumbled....More>>>
Source: ThinkstockJanuary 8, 2018: The S&P 500 closed up 0.2% at 2,747.45. The DJIA closedrelatively flat at 25,278.49. Separately, the Nasdaq was up 0.3% at 7,157.39.
Although Monday was a relatively mixed day for the markets, all three of the major exchanges hit all-time highs yet again. This is only the fifth trading day of the New Year and markets have been setting records on practically....More>>>
GOP Proposes Radical Change to 401(k) System
U.S. Stocks Should Terrify Janet Yellen: Billionaire Investor
Insurers Get 180 Days of SIFI Designation Relief
Advisors: Your valuable input is needed for our research. What factors weigh in on your use of ETFs in your business and how do you utilize them in your clients’ portfolios? Please take a few moments to participate....More>>>
Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
AT&T’s (NYSE:T) roll-out of the DirecTV Now service has been greeted by enthusiasm by some (me) and skepticism by others. The later camp notes that margins, at least on the introductory pricing, are likely to be slim and may cannibalize the company’s traditional DirecTV product offering.
In my mind, the DirecTV Now product was a forward-looking master stroke that begins....More>>>
bluebird bio, (NASDAQ:BLUE) is one of the oncology immunotherapy stocks I mentioned recently as worth a good look, (article titled ‘Immunotherapy Over Reaction’, a basic primer to the immunotherapy subsector and its ETF). BLUE is also a recent Cramer pick. Immunotherapy stocks have been hit hard over the summer but BLUE is a relatively highly valued genetic specialist, with some interesting....More>>>